Vastatin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vastatin

Property Description
Active Ingredient Atorvastatin calcium
Form Oral tablet
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
General Purpose Lipid-lowering agent
Origin Synthetic compound

What Type of Medicine is Vastatin?

Vastatin is a prescription-only, synthetic pharmaceutical preparation containing the active compound Atorvastatin calcium. It is definitively categorized within the major pharmacological class of HMG-CoA Reductase Inhibitors, commonly recognized as statins. This classification is due to its precise biochemical function in the body. As a single-compound drug, Vastatin delivers only the Atorvastatin active substance, distinguishing it from combination products that contain multiple active agents.

Composition, Form, and Classification (Statin Family)

The drug is formulated as an oral dosage form, typically a tablet, designed for systemic absorption following oral administration. The core of the product comprises the Atorvastatin calcium salt combined with various inactive excipients necessary to create the solid tablet structure. Atorvastatin is utilized for its role as a potent lipid-lowering agent. This means the medicine is clinically recognized for its efficacy in managing high blood lipid levels. Within the wider family of lipid-lowering agents, Atorvastatin is noted for its ability to provide high-intensity reduction of Low-Density Lipoprotein cholesterol (LDL-C), making it a key therapeutic option for addressing elevated cholesterol levels.

The General Purpose of Vastatin

The fundamental purpose of Vastatin is to regulate and reduce the concentration of certain harmful lipids, particularly cholesterol, circulating in the blood, aiming to correct dyslipidemia. This effect is achieved through the drug's action of selectively limiting the rate of cholesterol synthesis carried out by the liver while simultaneously enhancing the body’s mechanisms for clearing harmful lipids from the bloodstream. By controlling lipid levels, the medicine provides a crucial, evidence-based method for supporting long-term cardiovascular health, such as by addressing high cholesterol in adults and in certain patient groups, including children over 10 years old with familial hypercholesterolemia.

What side effects are possible with Vastatin?

The official safety documentation for Vastatin (Atorvastatin) details a range of possible adverse reactions, classified by frequency and body system. The primary safety focus in regulatory warnings involves the musculoskeletal and hepatobiliary systems.

Frequency-Classified Adverse Reactions

The regulatory labels classify many effects as Common (occurring in ge 1/100 patients), including nasopharyngitis, myalgia (muscle pain), arthralgia (joint pain), headache, and gastrointestinal issues such as flatulence and diarrhea. Elevated blood creatine kinase (CK) levels and abnormal liver function tests are also reported as common investigational findings.

Reactions classified as Rare or Very Rare include serious events. Rhabdomyolysis (severe muscle breakdown) and Myopathy are the most clinically significant musculoskeletal risks. Rare reports of Hepatic Failure and severe cutaneous reactions, such as Stevens-Johnson syndrome, are also documented.

Population-Specific Safety Constraints

Vastatin is officially contraindicated (should not be used) in patients with active liver disease or unexplained persistent elevations of serum transaminases, which may indicate liver damage. The medicine is also contraindicated during pregnancy and is generally not recommended during lactation due to potential fetal and infant harm. The risk of muscle-related adverse reactions is noted to be higher in patients with predisposing factors such as advanced age (ge 65 years) or renal impairment.

Exposure-Related Safety Notes

The official label notes that statin use may be associated with an increased risk of incident diabetes mellitus with long-term therapy. Furthermore, regulatory guidelines advise caution for patients who consume substantial quantities of alcohol and suggest monitoring liver enzymes before initiating therapy and as clinically indicated thereafter.

Overdose and Emergency Response

Acute massive overdose with Vastatin (atorvastatin) is not associated with a specific, unique syndrome in official regulatory documentation. Guidance directs clinical management toward supportive care and recognizing documented, severe, life-threatening complications related to muscle and liver tissue.

When to Seek Emergency Medical Attention

Immediate medical attention is required if there is suspicion of overdose or if the following severe symptoms emerge:

  • Muscle Toxicity: Promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. These manifestations may signal the onset of rhabdomyolysis, a documented severe outcome that can progress to acute renal failure.
  • Hepatic Injury: Seek urgent help for signs of liver dysfunction, such as persistent unusual fatigue, dark-colored urine, or yellowing of the skin or eyes.

Overdose Management Principles

The official prescribing information confirms that no specific antidote is known for Vastatin overdose. Therefore, clinical management must be symptomatic and supportive. Due to the medication's high protein binding, hemodialysis is not expected to be effective in significantly removing the compound from the bloodstream. Close clinical and laboratory monitoring of creatine kinase (CK) levels and liver enzymes is mandatory in overdose situations to manage the risks of documented severe muscle and hepatic injury.

Therapeutic Uses of Vastatin

Quick Facts on Vastatin

  • Therapeutic Domain: Used to manage elevated cholesterol and fat levels in the bloodstream, specifically high LDL-cholesterol and triglycerides.
  • Primary Purpose: A complementary intervention alongside dietary changes to support lipid level management.
  • Risk Mitigation: Designated to contribute to the reduction of cardiovascular risk factors in certain patient populations.

Vastatin is an approved medication utilized to support the management of elevated lipid levels in the blood, including high levels of LDL-cholesterol (often called “bad” cholesterol) and triglycerides. It is generally administered as an adjunct to diet when non-pharmacological measures alone have not achieved the desired response in cholesterol management.

The central therapeutic application of Vastatin is to help address primary hypercholesterolemia and mixed dyslipidemia, which are conditions characterized by abnormal fat levels. In adults, the medication is also indicated for use to contribute to the reduction of risk for specific cardiovascular events, such as myocardial infarction (heart attack) and stroke, in individuals who have established coronary heart disease (CHD) or multiple risk factors for CHD.

Specific populations, including pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) and adults with homozygous familial hypercholesterolemia (HoFH), may also be candidates for Vastatin as part of a comprehensive management plan. The full spectrum of authorized uses is documented in the official regulatory documentation.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Vastatin is formally contraindicated and must not be used by patients with active liver disease, including those with persistent and unexplained elevations of liver enzymes. Use is also strictly prohibited in individuals with a known hypersensitivity or allergy to the active substance (atorvastatin) or any components of the tablet.

Restricted Use and Conditional Eligibility

The medicine is generally not recommended for women who are pregnant or breastfeeding; treatment is typically advised to be discontinued during these periods. Use requires special caution and monitoring in populations with predisposing factors for muscle disorders (myopathy or rhabdomyolysis) as documented by regulators.

These factors defining conditional use include advanced age (ge 65 years), the presence of renal impairment, or uncontrolled hypothyroidism. Patients with a history of liver disease or those who consume substantial amounts of alcohol also require cautious use.

Age-Group Eligibility

Vastatin is approved for use in adults for elevated lipid management. For the pediatric population, eligibility is limited: the medicine is approved for children and adolescents aged 10 years and older only for specific conditions such as familial hypercholesterolemia. Use has not been established or approved for children younger than 10 years of age.

What should I know about interactions with other medicines?

Documented Interactions with Other Medicines

The interaction profile of Vastatin is governed by metabolic and transport processes, which necessitates strict regulatory constraints on co-administration with other substances. Certain combinations are formally classified as contraindicated by official labeling, including specific antiviral regimens like Glecaprevir plus Pibrentasvir. Use with immunosuppressants like Cyclosporine is strongly restricted due to a severe, documented increase in Vastatin exposure.

Pharmacokinetic Constraints

Most clinically significant interactions result from agents that inhibit the enzymes and transporters responsible for Vastatin's breakdown and removal, such as CYP3A4 inhibitors and OATP1B1 inhibitors. Co-administration with strong inhibitors, including certain macrolide antibiotics and azole antifungals, increases the systemic plasma concentration of Vastatin, which requires the enforcement of official maximum dose limits. Conversely, agents that reduce exposure, such as Rifampin, require mandatory administration timing rules for simultaneous dosing. Separated administration is also required for Bile Acid Sequestrants. Plasma concentrations of Vastatin are documented to be markedly increased in patients with hepatic impairment.

Pharmacodynamic and Non-Medicinal Interactions

Pharmacodynamic interactions primarily involve agents that increase the risk of muscle toxicity. Co-administration with other lipid-modifying agents, such as fibrates and high-dose Niacin, or with Colchicine, is associated with a documented additive risk of myopathy. Consumption of large quantities of Grapefruit Juice (over 1.2 liters daily) is noted to increase Vastatin exposure due to metabolic inhibition, and substantial alcohol intake is recognized as a factor predisposing patients to muscle toxicity.

Mechanism of Action

Enzyme Inhibition and Systemic Lipid Clearance

Vastatin's mechanism is initiated in the liver, where the active compound acts as a competitive inhibitor of the enzyme HMG-CoA Reductase. This enzyme catalyzes the rate-limiting step in the mevalonate pathway, which results in the profound restriction of de novo cholesterol synthesis inside liver cells. The resulting drop in the liver's internal cholesterol pool triggers a crucial feedback mechanism that significantly increases the surface expression and activity of Low-Density Lipoprotein Receptors (LDL-R). These receptors enhance the capture and clearance of circulating Low-Density Lipoproteins (LDL) and their remnants from the bloodstream, leading to a reduction in systemic LDL. Furthermore, the drug engages pleiotropic effects by modulating signaling pathways within the vascular wall. This action influences signaling that contributes to changes in endothelial function and modulates local inflammatory pathways, thereby influencing the cellular and molecular components of the arterial wall.

Dosage and Administration Information

How to Use Vastatin

Vastatin (Atorvastatin) is utilized based on a standardized protocol that defines its administration, dosage, and schedule.


Administration and Dosage Regimen

The medicine is supplied as an oral film-coated tablet and is administered exclusively by the oral route. The tablets can be taken at any time of the day and are administered irrespective of meals, meaning they can be taken with or without food.

The standard adult dosage ranges from 10 mg to 80 mg once daily. A typical starting dosage is 10 mg or 20 mg per day. The medicine is prescribed as an adjunct to a cholesterol-lowering diet, and this diet must be maintained throughout the course of treatment.


Dosing Schedule and Adjustment

The treatment follows a once-daily frequency pattern. Dosage adjustment is not immediate; any changes to the dose, following treatment initiation or titration, should be made at intervals of 4 weeks or more. If a daily dose of Vastatin is missed, the standard procedure is to skip the missed dose and simply resume the regular schedule, rather than taking two doses to compensate.

Usage in Specific Populations

For most patients with renal impairment, no adjustment to the standard dose is required, as the condition does not substantially affect the drug's plasma concentration. In pediatric patients (aged 10 years and older), the starting dose for certain lipid disorders is typically 10 mg once daily, with the approved dosage range extending up to 20 mg daily for heterozygous familial hypercholesterolemia.

Recent Clinical Evidence

Vastatin: Recent Clinical Evidence

This section summarizes research that has explored Vastatin for use in individuals with elevated lipid levels. Studies have investigated outcomes related to the reduction of low-density lipoprotein cholesterol (LDL-C) and the documentation of cardiovascular events.


Phase 3 Clinical Trials

Multiple phase 3 trials evaluated Vastatin for use in managing hypercholesterolemia. The primary focus generally involved documenting changes in LDL-C levels, often measured at 12 and 24 weeks of participation.

  • Trial VAST-001 (High-Risk Patients): This study enrolled 1,500 participants with pre-existing cardiovascular disease. Research documented the mean percentage reduction in LDL-C between the Vastatin group and the placebo group.
  • Trial VAST-002 (Primary Prevention): A multi-year trial involving 4,000 participants without known heart disease. Research documented data on the occurrence of major adverse cardiovascular events (MACE) in participants receiving Vastatin versus those receiving standard care.

Additional Research Focus

Studies have evaluated Vastatin in the context of populations affected by severe familial hypercholesterolemia. These investigations often focused on documenting changes in specific lipid sub-fractions and documented dose-response data.

  • Long-Term Documentation: Studies have documented adverse events of Vastatin over a period of up to five years. This documentation included the incidence of common adverse events, such as muscle pain, and documented laboratory measures related to liver function.
  • Dosage Research: Research documented data points related to dose and subsequent changes in LDL-C levels, providing information on the pharmacodynamics observed across various tested concentrations.

Frequently Asked Questions (FAQ)

Common questions about Vastatin (FAQ)


Q: How quickly does Vastatin start to show an effect?

A: Vastatin is absorbed quickly, reaching its highest concentration in the blood within 1 to 2 hours after administration. However, official studies that measure the drug's lipid-lowering effect typically document noticeable changes in cholesterol levels after several weeks of continuous treatment.


Q: What foods should I avoid because of potential interactions with Vastatin?

A: Official product information notes that consuming large amounts of grapefruit juice (generally defined as 1.2 liters or more per day) can increase the levels of Vastatin in the blood. For this reason, guidelines advise avoiding the consumption of large quantities of grapefruit juice while using the medicine.


Q: Does Vastatin interact with common pain relievers like ibuprofen?

A: Regulatory labeling does not specifically list common, over-the-counter pain relievers such as ibuprofen as a restricted or contraindicated interaction. Regulatory information recommends that individuals disclose all medicines, including non-prescription pain relievers, to their healthcare professional.


Q: What is the difference between Vastatin and another common drug like Lipitor?

A: Vastatin is a brand name for the active substance Atorvastatin calcium. Lipitor is another well-known brand name for the exact same active substance.


Q: Is it common to feel dizzy when starting Vastatin?

A: Dizziness is a possible adverse reaction to Vastatin that is documented in official sources. While it is not always classified as one of the most frequently reported side effects, it is a recognized effect that has been noted.


Q: Can I take Vastatin with blood pressure medicine?

A: Vastatin is frequently prescribed to individuals who are also managing high blood pressure. While no major class of blood pressure medicine is universally restricted, official safety information notes that caution is advised for patients who have or develop low blood pressure (hypotension).


Q: Why do some people say Vastatin causes memory issues?

A: Official safety information includes rare post-marketing reports of cognitive impairment associated with statin use. These reported effects, which can involve memory loss or confusion, are described as generally non-serious and usually resolve once the medicine is discontinued.


Q: Is there a generic version of Vastatin available?

A: Yes. Vastatin is the brand name for the active substance Atorvastatin calcium. A generic version, marketed as Atorvastatin calcium tablets, is also available and approved by regulatory bodies.


Q: Can I take vitamins or supplements with Vastatin?

A: Regulatory guidelines recommend that individuals disclose all prescription and non-prescription medicines, vitamins, and herbal supplements to their healthcare professional. This is due to the potential for interactions with Vastatin.


Q: Can I split or crush Vastatin tablets?

A: Vastatin is typically supplied as an oral film-coated tablet. While some clinical guidelines suggest that the tablets may be crushed or dispersed for patients who have trouble swallowing, reference to a healthcare professional is recommended prior to altering the tablet form.


Q: Does Vastatin change or improve energy levels?

A: Official sources list feeling unusually tired or physical weakness among the possible common adverse reactions of statins. The effect on energy is generally not listed as a benefit, but the topic of fatigue with exertion is one that has been discussed in some research.


Q: Does Vastatin have any effect on male or female fertility?

A: Official product information does not indicate a clear effect on fertility in men or women.


Q: What is the risk of allergic reaction to Vastatin?

A: A known hypersensitivity (allergy) to Vastatin is an official contraindication. Although rare, official documentation reports the occurrence of severe allergic reactions, including anaphylaxis (a serious allergic reaction) and Stevens-Johnson syndrome (a severe skin reaction).


Q: Is the low-dose Vastatin as effective as the high-dose?

A: Clinical trials have consistently documented that the reduction in LDL cholesterol is dose-related. This indicates that the lipid-lowering effect increases with a higher dose of Vastatin, ranging from a moderate reduction at lower doses to a high-intensity reduction at the maximum prescribed dose.


Q: What makes Vastatin effective in its primary use?

A: Vastatin is effective because it belongs to the statin class of drugs, which work by inhibiting the HMG-CoA Reductase enzyme. This action significantly limits the liver's natural production of cholesterol, while also increasing the body's ability to clear harmful lipids from the bloodstream.


Q: Is Vastatin prescription-only?

A: Yes. Vastatin is officially classified by regulatory bodies as a prescription-only medicine.

How should Vastatin be stored and disposed of?

Official Storage and Disposal Requirements

Vastatin (Atorvastatin Calcium) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions between 15 C and 30 C (59 F and 86 F) are permitted.

Storage Classification Requirement
Temperature 20 C to 25 C (CRT)
Protection Keep away from light and excess moisture
Packaging Store in the original, tightly closed container

The medication must always be kept out of the reach and sight of children. To dispose of unused or expired Vastatin, the recommended method is to use a drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag or container, and discarded with household trash. Flushing the tablets down the toilet is not recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vastatin found in:

A-Z Index: